CN104726439B - 一种广谱的链球菌裂解酶及其应用 - Google Patents
一种广谱的链球菌裂解酶及其应用 Download PDFInfo
- Publication number
- CN104726439B CN104726439B CN201510171835.8A CN201510171835A CN104726439B CN 104726439 B CN104726439 B CN 104726439B CN 201510171835 A CN201510171835 A CN 201510171835A CN 104726439 B CN104726439 B CN 104726439B
- Authority
- CN
- China
- Prior art keywords
- streptococcus
- clyr
- lyases
- purposes
- variety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000194017 Streptococcus Species 0.000 title claims abstract description 40
- 102000004317 Lyases Human genes 0.000 title claims abstract description 33
- 108090000856 Lyases Proteins 0.000 title claims abstract description 33
- 238000001228 spectrum Methods 0.000 title description 4
- 241000194042 Streptococcus dysgalactiae Species 0.000 claims abstract description 20
- 229940115920 streptococcus dysgalactiae Drugs 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 11
- 208000015181 infectious disease Diseases 0.000 claims abstract description 8
- 241000194019 Streptococcus mutans Species 0.000 claims abstract description 6
- 201000005010 Streptococcus pneumonia Diseases 0.000 claims abstract description 6
- 241000193998 Streptococcus pneumoniae Species 0.000 claims abstract description 6
- 241000193996 Streptococcus pyogenes Species 0.000 claims abstract description 6
- 241000194054 Streptococcus uberis Species 0.000 claims abstract description 6
- 229940115922 streptococcus uberis Drugs 0.000 claims abstract description 6
- 241000194033 Enterococcus Species 0.000 claims abstract description 5
- 241000193985 Streptococcus agalactiae Species 0.000 claims abstract description 5
- 241000194048 Streptococcus equi Species 0.000 claims abstract description 5
- 229940030998 streptococcus agalactiae Drugs 0.000 claims abstract description 5
- 241000588724 Escherichia coli Species 0.000 claims abstract description 4
- 238000000338 in vitro Methods 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 230000002147 killing effect Effects 0.000 claims description 6
- 239000008267 milk Substances 0.000 claims description 6
- 210000004080 milk Anatomy 0.000 claims description 6
- 235000013336 milk Nutrition 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 3
- 239000013613 expression plasmid Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 238000005342 ion exchange Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 claims 1
- 241000282898 Sus scrofa Species 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 abstract description 21
- 102000004190 Enzymes Human genes 0.000 abstract description 21
- 241000894006 Bacteria Species 0.000 abstract description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 14
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 7
- 239000011780 sodium chloride Substances 0.000 abstract description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract description 6
- 241000194021 Streptococcus suis Species 0.000 abstract description 5
- 231100000636 lethal dose Toxicity 0.000 abstract description 2
- 229940088598 enzyme Drugs 0.000 abstract 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 206010061372 Streptococcal infection Diseases 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 229960000856 protein c Drugs 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 22
- 239000007853 buffer solution Substances 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 241000191940 Staphylococcus Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 241001478240 Coccus Species 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 241000194035 Lactococcus lactis Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- 208000032923 Lobar pneumonia Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000194046 Streptococcus intermedius Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
- A23C9/1216—Other enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims (10)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510171835.8A CN104726439B (zh) | 2015-04-13 | 2015-04-13 | 一种广谱的链球菌裂解酶及其应用 |
US15/564,063 US9993532B2 (en) | 2015-04-13 | 2016-04-12 | Broad spectrum of Streptococcus lyase and use thereof |
AU2016248363A AU2016248363B2 (en) | 2015-04-13 | 2016-04-12 | Broad spectrum of streptococcus lyase and use thereof |
CA2981996A CA2981996C (en) | 2015-04-13 | 2016-04-12 | Broad spectrum of streptococcus lyase and use thereof |
PCT/CN2016/079043 WO2016165604A1 (zh) | 2015-04-13 | 2016-04-12 | 一种广谱的链球菌裂解酶及其应用 |
EP16779579.8A EP3312275B1 (en) | 2015-04-13 | 2016-04-12 | Antibiotic chimeric lyase from streptococcus and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510171835.8A CN104726439B (zh) | 2015-04-13 | 2015-04-13 | 一种广谱的链球菌裂解酶及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104726439A CN104726439A (zh) | 2015-06-24 |
CN104726439B true CN104726439B (zh) | 2017-11-14 |
Family
ID=53450855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510171835.8A Active CN104726439B (zh) | 2015-04-13 | 2015-04-13 | 一种广谱的链球菌裂解酶及其应用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9993532B2 (zh) |
EP (1) | EP3312275B1 (zh) |
CN (1) | CN104726439B (zh) |
AU (1) | AU2016248363B2 (zh) |
CA (1) | CA2981996C (zh) |
WO (1) | WO2016165604A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111803620A (zh) * | 2012-05-09 | 2020-10-23 | 康特拉费克特公司 | 使用噬菌体溶素的生物膜预防、破坏和处理 |
CN104726439B (zh) * | 2015-04-13 | 2017-11-14 | 武汉菲吉乐科生物科技有限公司 | 一种广谱的链球菌裂解酶及其应用 |
CN104805066B (zh) * | 2015-05-18 | 2018-04-24 | 武汉菲吉乐科生物科技有限公司 | 一种葡萄球菌裂解酶及其应用 |
CN107177580B (zh) * | 2017-06-05 | 2019-11-22 | 武汉赛思锐微生物技术有限公司 | 一种广谱新型嵌合裂解酶GBS-PlySb及其编码基因和应用 |
CN107022539B (zh) * | 2017-06-05 | 2020-05-22 | 武汉赛思锐微生物技术有限公司 | 一种链球菌广谱嵌合裂解酶GBS-V12b及其编码基因和应用 |
CN110592057B (zh) * | 2019-09-27 | 2022-01-28 | 昆明理工大学 | 嵌合裂解酶ILTphg和编码此酶的多核苷酸 |
CN111358770A (zh) * | 2020-03-25 | 2020-07-03 | 天津大学 | 一种牙周炎治疗凝胶贴片制剂的合成方法 |
CN112501189A (zh) * | 2020-12-30 | 2021-03-16 | 吉林大学 | 一种能杀死马链球菌马亚种的裂解酶及其医用用途 |
CN113201523A (zh) * | 2021-05-17 | 2021-08-03 | 吉林大学 | 一种特异性杀灭猪链球菌的基因工程裂解酶及医用用途 |
CN113549610B (zh) * | 2021-07-05 | 2022-11-11 | 中国科学院武汉病毒研究所 | 一种具有广谱裂解活性的抗菌肽P104、裂解酶LysP53及其应用 |
CN116640755B (zh) * | 2023-07-21 | 2023-10-20 | 临沂大学 | 一种链球菌前噬菌体裂解酶lys1519及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1390134A (zh) * | 1999-09-14 | 2003-01-08 | 新眼界诊断公司 | 噬菌体相关裂解酶对各种疾病的预防性和治疗性处理的用途 |
CN103122347A (zh) * | 2013-02-01 | 2013-05-29 | 中国科学院武汉病毒研究所 | 一种杀灭葡萄球菌的裂解酶及其应用 |
CN103146666A (zh) * | 2013-03-20 | 2013-06-12 | 南京农业大学 | 猪链球菌胞壁水解酶、其编码基因及应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004104213A2 (en) * | 2003-05-15 | 2004-12-02 | The Rockefeller University | Nucleic acids and polypeptides of c1 bacteriophage and uses thereof |
US7572602B1 (en) * | 2004-12-03 | 2009-08-11 | The United States Of America As Represented By The Secretary Of Agriculture | Nucleic acid encoding endolysin fusion protein |
US8951532B2 (en) * | 2010-01-25 | 2015-02-10 | Alere Scarborough, Inc. | A25 bacteriophage lysin |
US8962297B2 (en) * | 2010-09-01 | 2015-02-24 | The United States Of America, As Represented By The Secretary Of Agriculture | Bacteriophage lytic enzymes as alternative antimicrobials |
CN102181420A (zh) * | 2011-01-31 | 2011-09-14 | 上海交通大学 | 猪链球菌噬菌体裂解酶的乳酸乳球菌表达方法 |
WO2012145573A2 (en) * | 2011-04-21 | 2012-10-26 | Universiteit Utrecht Holding Bv | Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock |
JP6139509B2 (ja) * | 2011-04-21 | 2017-05-31 | ザ ロックフェラー ユニバーシティ | グラム陽性細菌を検出および処置するためのStreptococcusバクテリオファージリシン |
CN104726439B (zh) * | 2015-04-13 | 2017-11-14 | 武汉菲吉乐科生物科技有限公司 | 一种广谱的链球菌裂解酶及其应用 |
-
2015
- 2015-04-13 CN CN201510171835.8A patent/CN104726439B/zh active Active
-
2016
- 2016-04-12 WO PCT/CN2016/079043 patent/WO2016165604A1/zh active Application Filing
- 2016-04-12 EP EP16779579.8A patent/EP3312275B1/en active Active
- 2016-04-12 US US15/564,063 patent/US9993532B2/en active Active
- 2016-04-12 AU AU2016248363A patent/AU2016248363B2/en active Active
- 2016-04-12 CA CA2981996A patent/CA2981996C/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1390134A (zh) * | 1999-09-14 | 2003-01-08 | 新眼界诊断公司 | 噬菌体相关裂解酶对各种疾病的预防性和治疗性处理的用途 |
CN103122347A (zh) * | 2013-02-01 | 2013-05-29 | 中国科学院武汉病毒研究所 | 一种杀灭葡萄球菌的裂解酶及其应用 |
CN103146666A (zh) * | 2013-03-20 | 2013-06-12 | 南京农业大学 | 猪链球菌胞壁水解酶、其编码基因及应用 |
Non-Patent Citations (2)
Title |
---|
"GenBank Accession No:NP_852017.2";登录号;《GenBank》;20090417;第1页的ORIGIN部分 * |
"GenBank Accession No:WP_014636660.1";登录号;《GenBank》;20130528;第1页的ORIGIN部分 * |
Also Published As
Publication number | Publication date |
---|---|
US20180104316A1 (en) | 2018-04-19 |
EP3312275A1 (en) | 2018-04-25 |
AU2016248363A1 (en) | 2017-11-02 |
CN104726439A (zh) | 2015-06-24 |
US9993532B2 (en) | 2018-06-12 |
AU2016248363B2 (en) | 2022-01-20 |
EP3312275A4 (en) | 2018-09-19 |
EP3312275B1 (en) | 2022-04-27 |
CA2981996C (en) | 2022-07-26 |
WO2016165604A1 (zh) | 2016-10-20 |
CA2981996A1 (en) | 2016-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104726439B (zh) | 一种广谱的链球菌裂解酶及其应用 | |
Zhao et al. | The g-type lysozyme of Scophthalmus maximus has a broad substrate spectrum and is involved in the immune response against bacterial infection | |
CN107189997A (zh) | 用于革兰氏阳性菌检测和治疗的链球菌属细菌噬菌体溶素 | |
CN110846283B (zh) | 宽裂解谱的大肠杆菌噬菌体及其组合物、试剂盒和应用 | |
CN107177580B (zh) | 一种广谱新型嵌合裂解酶GBS-PlySb及其编码基因和应用 | |
CN107022539A (zh) | 一种链球菌广谱嵌合裂解酶GBS‑V12b及其编码基因和应用 | |
CN107779439A (zh) | 新的葡萄球菌噬菌体及其组合物、制备方法和应用 | |
CN107058265A (zh) | 铜绿假单胞菌噬菌体裂解酶及应用 | |
CN103468673A (zh) | 一种抗菌肽的制备方法和应用 | |
CN105324481A (zh) | 新颖噬菌体和包括所述新颖噬菌体的抗细菌组成物 | |
CN104805066B (zh) | 一种葡萄球菌裂解酶及其应用 | |
CN104830825B (zh) | 一种来源于沙门氏菌噬菌体的内溶素及其应用 | |
CN104593346A (zh) | 一种来源于副溶血弧菌噬菌体的内溶素及其应用 | |
CN103122347B (zh) | 一种杀灭葡萄球菌的裂解酶及其应用 | |
Mahdhi et al. | Survival and retention of the probiotic properties of Bacillus sp. strains under marine stress starvation conditions and their potential use as a probiotic in Artemia culture | |
CN102198265A (zh) | 应用噬菌体裂解酶降解猪链球菌生物被膜的方法 | |
CN103525782A (zh) | 一种突变的有机磷农药降解酶基因及其应用 | |
CN101703769B (zh) | 一种新型猪链球菌病四价灭活疫苗 | |
CN103387992A (zh) | 编码重组猪β-防御素-1的基因及猪β-防御素-1的制备方法 | |
CN107988189B (zh) | 一种绿脓杆菌中的酶FadD1在降解DSF家族信号分子中的应用 | |
CN105543258A (zh) | 一种类志贺邻单胞菌噬菌体裂解酶的制备方法及其抗菌应用 | |
CN108823193A (zh) | 一种高效肺炎链球菌嵌合裂解酶及其突变体与应用 | |
Du et al. | Pathology of extracellular protease of Stenotrophomonas maltophilia isolated from channel catfish (Ictalunes punctatus) to mice | |
Dutta et al. | Bacteriophage therapy to combat antibiotic resistance: a brief review | |
KR20060113571A (ko) | 수질정화용 항균기능을 가진 세라믹혼합물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Wuhan Faye Gile C biological science and Technology Co.,Ltd. Office Document name: Notification that Application Deemed not to be Proposed |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160405 Address after: 430075 A7 Exhibition Center of biomedicine Park, 858 hi tech Avenue, East Lake New Technology Development Zone, Wuhan, Hubei Applicant after: WUHAN PHAGELUX BIO-TECH Co.,Ltd. Address before: 2, building 430075, building B7, 666 hi tech Avenue, East Lake Development Zone, Hubei, Wuhan, 513 Applicant before: Wuhan Phagelux Bio-tech Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201124 Address after: Co services Cayman limited, P.O. Box 10008 willow house, cricket square, Grand Cayman Islands Patentee after: Figelok Co.,Ltd. Address before: 430075 A7 Exhibition Center of biomedicine Park, 858 hi tech Avenue, East Lake New Technology Development Zone, Wuhan, Hubei Patentee before: Wuhan Phagelux Bio-tech Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231009 Address after: Room 201, 1012 College Road, Dover, Delaware, United States Patentee after: Targeted Antibiotics Biopharmaceutical Technology Co.,Ltd. Address before: Co services Cayman limited, P.O. Box 10008 willow house, cricket square, Grand Cayman Islands Patentee before: Figelok Co.,Ltd. |